Navigation Links
Uroplasty Expands Marketing Program for Urology Practices
Date:1/17/2008

- Program To Help Create Awareness of a Non-Invasive Treatment Option for

Overactive Bladder Symptoms -

MINNEAPOLIS, Jan. 17 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) today announced the expansion of its CO-OP marketing program to customers of its Urgent PC(R) neuromodulation system for the treatment of overactive bladder (OAB) symptoms. Uroplasty offers this marketing program to customers who wish to promote the availability in their practice of this leading non-surgical, office-based treatment option.

"This is the right time to offer an expanded marketing program to our fast-growing base of customers," said David B. Kaysen, Uroplasty's President and CEO. "In the quarter ended December 31, 2007 we had over 300 active customers in the United States, consisting primarily of urologists and urogynecologists, who purchased our Urgent PC neuromodulation system or additional lead sets. This represents in excess of a 150% increase from 119 active customers we had in our fourth fiscal quarter ended March 31, 2007. Our expanded marketing program gives our customers more options to enhance their practice, and market the benefits and availability of the Urgent PC system to their patients."

Kaysen continued, "Our focus in the U.S. is to both expand our new customer base and increase our revenue from our existing customer base. We believe this marketing program, an important part of our growth strategy, will allow our customers to increasingly incorporate the Urgent PC system as part of the treatment option they offer to their patients."

Program participants, working closely with Uroplasty, select a marketing program suitable for their practice from a menu of options which includes local media print advertising, patient and physician education seminars, direct mail campaign, and local radio advertising. Uroplasty and the participant share the marketing program costs in proportion to the benefit each receives from the program.

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of OAB symptoms of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms of OAB. Uroplasty sells the Urgent PC system in the United States, Canada and countries recognizing the CE mark. Outside of the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder (OAB) symptoms. We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.

Safe Harbor

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. This press release contains forward-looking statements, which reflect our views regarding future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, including those identified below, which could cause actual results to differ materially from historical results or those anticipated. The words "aim," "believe," "expect," "anticipate," "intend," "estimate" and other expressions, which indicate future events and trends, identify forward-looking statements. Actual future results and trends may differ materially from historical results or those anticipated depending upon a variety of factors, including, but not limited to: the effect of government regulation, including when and if we receive approval for marketing products in the United States; the impact of international currency fluctuations on our cash flows and operating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, our historical reliance on a single product for most of our current sales; our ability to commercialize our recently licensed product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of clinical trials; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price. We cannot assure that we can successfully expand our U.S. field sales force, that our active customer base will continue to grow or that we will be successful in helping our active customers introduce, and our existing customers will continue to market, our Urgent PC technology. Uroplasty undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer,

952.426.6140

EVC Group

Doug Sherk/Julie Huang/Matt Selinger (Investors)

646.443.6963

Steve DiMattia (Media)

646.201.5445


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
2. Uroplasty to Host Second Quarter Conference Call on November 1
3. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
4. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
5. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
6. Rohm and Haas Expands in India
7. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
8. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
9. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
10. Specialty Blades, Inc. Expands Management Team With New VP Engineering
11. CRH Medical expands Las Vegas operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology: